Ardelyx Inc

Ardelyx insider buying spurs confidence: Chief Legal Officer’s new 237,000‑share stake signals bullish outlook, regulatory strength and potential earnings upside.

Ardelyx insider moves show confidence, not panic—RSUs and balanced trades amid strong phase‑2 success and phase‑3 enrollment could boost stock toward its 52‑week peak.

Ardelyx CEO’s strategic 10 b‑5‑1 trades show confidence and long‑term alignment—buy low, sell wisely—offering investors insight into future growth plans.

Insider Mott David M buys 333k Ardelyx shares at $5.84, signalling confidence amid volatility and a potential catalyst for upside if clinical milestones hit.

Ardelyx insider buy by Chief Patient Officer Laura Williams shows confidence amid social‑media buzz and a bullish pipeline for IBSRELA and XPHOZAH, yet option sales signal risk‑aware management.